Sign In
Buy GPCR
$37.50
+0.310 (+0.83%)
At Close: Jun 03, 2026
Structure Therapeutics Announces Participation in Upcoming Investor Conferences
04:05pm, Tuesday, 26'th May 2026
SAN FRANCISCO, May 26, 2026 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for meta
If Viking Therapeutics Is Acquired, Here’s Who Wins
08:50am, Tuesday, 26'th May 2026
Polymarket traders are watching one biotech more closely than any other for an acquisition. Viking Therapeutics (NASDAQ: VKTX) carries a 38.5% implied probability of being acquired before 2027, with a
This Biotech Is Up 60%. A Top Healthcare Fund Just Bought Another $11 Million
10:19am, Sunday, 24'th May 2026
Structure Therapeutics advances oral therapies for chronic diseases, with a pipeline focused on metabolic and pulmonary conditions.
Can Mounjaro, Zepbound & Foundayo Keep Fueling LLY's Growth Story?
12:36pm, Thursday, 21'st May 2026
Eli Lilly's GLP-1 portfolio is driving growth in 2026, with Mounjaro, Zepbound and Foundayo gaining traction across obesity, diabetes and related markets.
Monashee Scales Back Its Bet on Structure Therapeutics
03:27pm, Wednesday, 20'th May 2026
This clinical-stage biotech develops oral therapies for chronic diseases, with a lead candidate targeting type-2 diabetes and obesity.
This Obesity Drug Stock Has Jumped 60% as Phase 3 Plans Advance. A Fund Just Sold $4.7 Million
02:22pm, Sunday, 17'th May 2026
This clinical-stage biotech develops oral therapeutics for chronic diseases, with a pipeline centered on metabolic and pulmonary targets.
Can Novo Nordisk Sustain Its GLP-1 Edge Amid Lilly's Growing Pressure?
11:20am, Thursday, 14'th May 2026
NVO beats Q1 estimates and raises its 2026 outlook. Meanwhile, Eli Lilly's expanding GLP-1 portfolio threatens its obesity market dominance.
Lilly Bets on Next-Generation Obesity Drugs to Stay Ahead
12:52pm, Wednesday, 13'th May 2026
LLY expands beyond tirzepatide with oral obesity pills and next-gen drugs like retatrutide to defend its lead in the booming weight-loss market.
Nxera Pharma Announces Progress of Out-Licensing of GPCR-targeted Program and Participation in Series A Financing
02:35am, Monday, 11'th May 2026
Tokyo, Japan and Cambridge, UK, 11 May 202 6 – As announced on 12 February 2026, Nxera Pharma Co., Ltd. (“Nxera” or the “Company”) entered into a license agreement with a newly established c
Structure Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights
04:05pm, Thursday, 07'th May 2026
Reported positive results from aleniglipron Phase 2 ACCESS II study with up to 16.3% body weight loss, demonstrating highest efficacy among oral GLP-1RAs at the 44-week time point and potentially co
SAN FRANCISCO, April 27, 2026 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for me
3 Ways to Invest in the Growing GLP-1 Weight Loss Market
11:20am, Friday, 17'th Apr 2026
Weight loss drugs are big business, with the GLP-1 receptor agonist market expected to nearly triple in size to $185 billion by 2033, a compound annual growth rate of about 12.4%. Although increasingl
Structure Therapeutics Appoints Matthew Lang, J.D. as Chief Operating Officer and General Counsel
04:05pm, Tuesday, 14'th Apr 2026
SAN FRANCISCO, April 14, 2026 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for me
Structure Therapeutics: The Oral Obesity Inflection, Best-In-Class Efficacy Meets Biased-Agonism Safety Moat
04:14pm, Wednesday, 08'th Apr 2026
Structure Therapeutics (GPCR) is initiated with a BUY rating and $110 price target, reflecting a 101% upside from current levels. Aleniglipron, GPCR's oral GLP-1 agonist, demonstrated 16.3% placebo-ad
Capricorn Fund Managers Ltd Invests $17.57 Million in Structure Therapeutics Inc. Sponsored ADR $GPCR
04:43am, Monday, 06'th Apr 2026
Capricorn Fund Managers Ltd bought a new stake in shares of Structure Therapeutics Inc. Sponsored ADR (NASDAQ: GPCR) during the fourth quarter, according to the company in its most recent disclosure w
